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The Importance of the Coalition of Skin 
Diseases to Dermatologic Research
Successful clinical investigation requires financial resources, patients with one or more identified diseases, personnel to con-
duct the research, and good hypotheses. Those 
who choose to conduct clinical studies soon 
learn that investigation is largely a business, 
even when it occurs in academic medical cen-
ters and research institutes. For example, access 
to money is often the “rate-limiting” step. This is 
true for all varieties of clinical research, ranging 
from case reports written by physicians in prac-
tice to complex multidisciplinary projects that 
cost millions of dollars (or Euros). Appropriate 
amounts of money buy time for investigators to 
develop good ideas, qualified personnel to con-
duct the laboratory work, space in which to con-
duct the work, essential materials, and, finally, 
time to prepare manuscripts and reports for pub-
lication and distribution.
Given this requirement for financial resources, 
productive investigators have necessarily devised 
various strategies for their generation. For exam-
ple, physicians who write papers about patients 
seen in clinical practice have less time to provide 
medical care, thereby lowering cash flow and 
personal income, while at the same time hope-
fully increasing satisfaction. Thus, they support 
their work with their own funds. At the other end 
of the spectrum, investigators in departments 
of dermatology and basic science departments 
attempt to divert scarce institutional resources 
toward their own interests. At the same time, a 
large investigative effort in skin disease is con-
ducted by for-profit companies, with the goal of 
developing drugs and equipment that ultimately 
will offset their costs. And finally—the object of 
this editorial—in North America and Europe, 
investigators apply for resources from national 
governments and from private funding agen-
cies to support their work. In the United States, 
the National Institutes of Health (NIH) provides 
through grants and contracts major amounts 
of money. The same is true in Europe, albeit 
through national and EU sources.
In recent decades, several “not-for-profit” 
advocacy organizations have become critical 
players in the generation of national resources, 
as well as in providing necessary information to 
patients with specific diseases. These organiza-
tions, having mandates to address the needs of 
patients with specific diseases, now assist in the 
recruitment of money to support research and 
advocate the advancement of research in these 
disease categories. We first became acquainted 
with patient advocacy many years ago through 
activities of the National Psoriasis Foundation 
and then the Alopecia Areata Foundation, both 
chartered in the United States. Importantly, in 
more recent years, these organizations and many 
others have consolidated some of their efforts 
and resources in a collective organization now 
known as the Coalition of Skin Diseases (http://
www.coalitionofskindiseases.org). We invite 
readers to consult this website to become more 
familiar with the member organizations.
The Coalition of Skin Diseases current-
ly encompasses 16 organizations that pool 
their efforts, while at the same time providing 
resources for their own specific interests. Their 
activities include patient information resources, 
direct funding for research, and lobbying at the 
national level. In addition, other organizations 
with more general interests support the coalition, 
including five that are well known in the United 
States: the American Academy of Dermatology 
(AAD); the American Skin Association, Inc.; the 
Dermatology Nurses Association; the Society for 
Investigative Dermatology (SID); and the Society 
for Pediatric Dermatology. We highly recom-
mend that readers study the great variety of 
resources and efforts provided by the coalition.
A simple personal experience illustrates the 
power of the Coalition of Skin Diseases. For 
many years, members of the coalition, along 
with representatives from the SID and the AAD, 
and supported by representatives of the National 
Institute for Arthritis and Musculoskeletal and 
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Skin Diseases, have held an annual education event for 
members of Congress in Washington, DC. The point of 
this exercise, which continues today, is to keep research 
opportunities and activities on the agenda for members of 
Congress, who ultimately are responsible for funding by the 
NIH. For more than 10 years, I participated in this event. It 
was organized to enable small groups to visit congressional 
offices and to promote medical research in general, using evi-
dence about patients with skin diseases. Each group includes 
at least one individual from a congressional district (or from 
a state when visiting a Senate office), one individual from an 
advocacy group, and one scientist. These groups then visit 
congressional “staffers,” or, if lucky, the member of Congress. 
The reception is invariably cordial.
Perhaps the most telling observation from these visits is that 
staffers and congressional representatives embrace the coali-
tion members, but are not especially interested in speaking to 
the scientists, at least initially. I surmise that my presence (as a 
scientist) might be seen as self-serving because investigator sal-
aries are included in grant requests to the NIH.  On the other 
hand, members of the coalition have no apparent conflict of 
interest. They are strictly advocates for research funding, seek-
ing benefits only for patients.  They know the diseases, and 
they describe them well. The visual materials they present are 
outstanding and overwhelming, as images of skin diseases 
usually are.  In these meetings, it is a relief to hear the coalition 
members state authoritatively their advocacy for funding by 
federal agencies, including the NIH and the National Science 
Foundation. We scientists can then affirm our interest in 
studying the disease for the benefit of others.
The Coalition of Skin Diseases is an effective propo-
nent of skin research, through both funding and advocacy, 
and their efforts should be supported by members of the 
scientific community. Their interests are the same as ours: 
the alleviation of disease. Scientists who care for patients 
should recommend membership to their patients and, as 
members of the SID, we should encourage membership by 
our colleagues on their advisory boards. At the next Annual 
Meeting of the SID, seek out members of the coalition to 
learn more about their agenda.
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